<DOC>
	<DOC>NCT01768286</DOC>
	<brief_summary>This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir fixed dose combination (FDC) with or without ribavirin (RBV) administered for 12 or 24 weeks in treatment-experienced subjects with chronic genotype 1 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination Â± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
	<criteria>Age &gt; 18, with chronic genotype 1 HCV infection HCV treatmentexperienced, including patients who have previously failed a nonstructural protein (NS)3/4A protease inhibitor plus pegylated interferon (PEG)/RBV regimen HCV RNA &gt; 10,000 IU/mL at screening Cirrhosis determination; a liver biopsy may be required Screening laboratory values within defined thresholds Use of two effective contraception methods if female of childbearing potential or sexually active male Pregnant or nursing female or male with pregnant female partner Coinfection with HIV or hepatitis B virus Current or prior history of clinical hepatic decompensation Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers) Chronic use of systemic immunosuppressive agents History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>HCV genotype 1 (GT-1)</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>GS-7977</keyword>
	<keyword>GS-5885</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Open Label</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Additional relevant MeSH terms:</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis, Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C, Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis, Viral, Human</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Enterovirus Infections</keyword>
	<keyword>Picornaviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms of Pharmacological Action</keyword>
</DOC>